FDA
-
-
-
-
-
-
-
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
-
-
-
-
-
-
-
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
-
-
-
-
-
-
-
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
-
-
-
-
-
-
-
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
-
-
-
-
-
-
-
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
-
-
-
-
-
-
-
enVVeno Medical (NVNO) Appoints Sandy Prietto as VP of Marketing
-
-
-
-
-
-
-
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
-
325,894 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

